IL6 and Huntington disease: The research by Hung et al. [25], which showed that treating HD patients with IL-1 receptor antagonist (IL-1ra) resulted in a dramatic decrease in the blood levels of IL-6 and CRP without compromising hemodynamic stability or dialysis effectiveness supporting IL-1β as an upstream contributor to systemic inflammation.